Select a medication above to begin.
Recombivax HB
hepatitis B vaccine (recombinant) (HepB)
Adult Dosing .
Dosage forms: INJ
hepatitis B infection prevention, immunocompetent patients
- [<20 yo]
- Dose: 5 mcg IM x1 at mo 0, 1, and 6 for 3 total doses; Info: may give SC if hemorrhage risk w/ IM; repeat series if anti-HBs level <10 milliunits/mL at least 1-2mo after 3rd dose in healthcare workers or patients w/ HBsAg-positive sex partner; search 'immunization' for epocrates Adult Immunization and CDC Pre-Travel Vaccine decision tools incl. links to CDC/ACIP schedules and recommendations
- [20 yo and older]
- Dose: 10 mcg IM x1 at mo 0, 1, and 6 for 3 total doses; Info: give to patients 60 yo and older w/ risk factors; may give to patients 60 yo and older w/o risk factors; may give SC if hemorrhage risk w/ IM; repeat series if anti-HBs level <10 milliunits/mL at least 1-2mo after 3rd dose in healthcare workers or patients w/ HBsAg-positive sex partner; search 'immunization' for epocrates Adult Immunization and CDC Pre-Travel Vaccine decision tools incl. links to CDC/ACIP schedules and recommendations
hepatitis B infection prevention, immunocompromised patients (off-label)
- [patients w/ HIV infection]
- Dose: 20 mcg IM x1 at mo 0, 1, and 6 for 3 total doses; Info: may give SC if hemorrhage risk w/ IM; repeat series if anti-HBs level <10 milliunits/mL at least 1-2mo after 3rd dose; refer to DHHS guidelines for dosing in patients w/ isolated anti-HBc
- [patients w/o HIV infection]
- Dose: 40 mcg IM x1 at mo 0, 1, and 6 for 3 total doses; Info: for patients 20 yo and older; may give SC if hemorrhage risk w/ IM; repeat series if anti-HBs level <10 milliunits/mL at least 1-2mo after 3rd dose
renal dosing
- [<20 yo]
- renal impairment: consider incr. usual dose or frequency if eGFR <30
- HD/PD: no adjustment; no supplement
- [20 yo and older]
- renal impairment: consider incr. usual dose or frequency if eGFR <30
- HD/PD: 40 mcg x1 at mo 0, 1, and 6 for 3 total doses; repeat series if anti-HBs level <10 milliunits/mL 1-2mo after 3rd dose; give 40 mcg booster x1 if annual anti-HBs level <10 milliunits/mL; no supplement
hepatic dosing
- [no adjustment]
Peds Dosing .
- Dosage forms: INJ
hepatitis B infection prevention, primary
- [newborn w/ HBsAg-negative gestational parent]
- Dose: 5 mcg IM x1 at birth, 1-2 mo, and 6-18 mo for 3 total doses; Start: w/in 24h of birth if wt >2 kg, otherwise at 1 mo or hospital discharge; Info: may give SC if hemorrhage risk w/ IM; search 'immunization' for epocrates Child/Adolescent Immunization and CDC Pre-Travel Vaccine decision tools incl. links to CDC/ACIP schedules and recommendations
- [newborn w/ HBsAg-positive gestational parent]
- Dose: 5 mcg IM x1 at birth, 1-2 mo, and 6-18 mo for 3 total doses; Start: w/in 12h of birth; Info: may give SC if hemorrhage risk w/ IM; give w/ hepatitis B immune globulin; if wt <2 kg, give 1 dose at birth, then start 3-dose series at 1 mo for 4 total doses; search 'immunization' for epocrates Child/Adolescent Immunization and CDC Pre-Travel Vaccine decision tools incl. links to CDC/ACIP schedules and recommendations
- [newborn w/ HBsAg status unknown gestational parent]
- Dose: 5 mcg IM x1 at birth, 1-2 mo, and 6-18 mo for 3 total doses; Start: w/in 12h of birth; Info: may give SC if hemorrhage risk w/ IM; if wt <2 kg, give 1 dose at birth w/ hepatitis B immune globulin, then start 3-dose series at 1 mo for 4 total doses; search 'immunization' for epocrates Child/Adolescent Immunization and CDC Pre-Travel Vaccine decision tools incl. links to CDC/ACIP schedules and recommendations
- [immunocompetent patients, <11 yo]
- Dose: 5 mcg IM x1 at mo 0, 1-2, and 6-18 for 3 total doses; Info: may give SC if hemorrhage risk w/ IM; search 'immunization' for epocrates Child/Adolescent Immunization and CDC Pre-Travel Vaccine decision tools incl. links to CDC/ACIP schedules and recommendations
- [immunocompetent patients, 11-15 yo]
- Dose: 5 mcg IM x1 at mo 0, 1-2, and 6-18 for 3 total doses; Alt: 10 mcg IM x2 doses at least 4mo apart; Info: may give SC if hemorrhage risk w/ IM; search 'immunization' for epocrates Child/Adolescent Immunization and CDC Pre-Travel Vaccine decision tools incl. links to CDC/ACIP schedules and recommendations
- [immunocompetent patients, 16 yo and older]
- Dose: 5 mcg IM x1 at mo 0, 1-2, and 6-18 for 3 total doses; Info: may give SC if hemorrhage risk w/ IM; search 'immunization' for epocrates Child/Adolescent Immunization and CDC Pre-Travel Vaccine decision tools incl. links to CDC/ACIP schedules and recommendations
- [immunocompromised adolescents (off-label)]
- Dose: 20 mcg IM x1 at mo 0, 1, and 6 for 3 total doses; Info: for patients w/ HIV infection; may give SC if hemorrhage risk w/ IM; repeat series if anti-HBs level <10 milliunits/mL at least 1-2mo after 3rd dose; refer to DHHS guidelines for dosing in patients w/ isolated anti-HBc
hepatitis B infection prevention, booster (off-label)
- [5 mcg IM x1]
- Info: for patients >9 mo w/ HBsAg-positive or HBsAg status unknown gestational parent and anti-HBs level <10 milliunits/mL at least 1-2mo after last dose of primary series; may give SC if hemorrhage risk w/ IM; give subsequent doses per schedule to complete second series if anti-HBs level <10 milliunits/mL at least 1-2mo after booster dose
renal dosing
- [see below]
- renal impairment: consider incr. usual dose or frequency if eGFR <30
- HD/PD: no adjustment; no supplement
hepatic dosing
- [no adjustment]
Contraindications / Cautions .
- hypersensitivity to drug or ingredient
- hypersensitivity to yeast
- caution: hypersensitivity to latex
- caution: immunocompromised patients
- caution: illness, acute moderate-severe
- caution: patients >60 yo
- caution: renal impairment
Drug Interactions .
Overview
hepatitis B vaccine
vaccine
- non-live vaccine
Avoid/Use Alternative
- interferon gamma 1b
Monitor/Modify Tx
- abatacept
- abemaciclib
- abrocitinib
- acalabrutinib
- adalimumab
- ado-trastuzumab emtansine
- afamitresgene autoleucel
- aldesleukin
- alemtuzumab
- anakinra
- anifrolumab
- anti-thymocyte globulin
- atezolizumab
- atidarsagene autotemcel
- avelumab
- avutometinib
- axicabtagene ciloleucel
- azacitidine
- azathioprine
- baricitinib
- basiliximab
- belatacept
- belimumab
- belinostat
- belzutifan
- bendamustine
- betamethasone
- bimekizumab
- blinatumomab
- bortezomib
- brentuximab vedotin
- brexucabtagene autoleucel
- brodalumab
- budesonide
- budesonide rectal
- busulfan
- cabazitaxel
- canakinumab
- capecitabine
- capmatinib
- carboplatin
- carfilzomib
- carmustine
- cemiplimab
- certolizumab pegol
- chlorambucil
- ciltacabtagene autoleucel
- cisplatin
- cladribine injection
- cladribine oral
- clofarabine
- copanlisib
- corticotropin
- cortisone
- cosibelimab
- cyclophosphamide
- cyclosporine
- cytarabine
- dactinomycin
- daratumumab
- dasatinib
- daunorubicin
- decitabine
- defactinib
- deflazacort
- delgocitinib topical
- deucravacitinib
- deuruxolitinib
- dexamethasone
- dimethyl fumarate
- dinutuximab
- diroximel fumarate
- docetaxel
- dordaviprone
- dostarlimab
- doxorubicin
- dupilumab
- durvalumab
- duvelisib
- efgartigimod alfa
- elivaldogene autotemcel
- elotuzumab
- elranatamab
- emapalumab
- epcoritamab
- epirubicin
- eribulin
- etanercept
- etoposide
- etrasimod
- everolimus
- fam-trastuzumab deruxtecan
- fingolimod
- floxuridine
- fludarabine
- fludrocortisone
- fluorouracil
- fruquintinib
- gemcitabine
- gemtuzumab ozogamicin
- glofitamab
- golimumab
- guselkumab
- hydrocortisone
- hydroxyurea
- ibritumomab tiuxetan
- ibrutinib
- idarubicin
- idecabtagene vicleucel
- idelalisib
- ifosfamide
- imatinib
- inebilizumab
- infliximab
- inotuzumab ozogamicin
- ipilimumab
- irinotecan
- isatuximab
- ixabepilone
- ixekizumab
- lebrikizumab
- leflunomide
- lenalidomide
- linvoseltamab
- lisocabtagene maraleucel
- lomustine
- loncastuximab tesirine
- lurbinectedin
- lymphocyte immune globulin, anti-thymocyte globulin
- margetuximab
- melphalan
- mercaptopurine
- methotrexate
- methylprednisolone
- mirikizumab
- mitomycin
- mitoxantrone
- mogamulizumab
- momelotinib
- monomethyl fumarate
- mosunetuzumab
- mycophenolate mofetil
- mycophenolic acid
- natalizumab
- nelarabine
- nemolizumab
- nilotinib
- nipocalimab
- nivolumab
- obecabtagene autoleucel
- obinutuzumab
- ocrelizumab
- ofatumumab
- oxaliplatin
- ozanimod
- paclitaxel
- palbociclib
- panobinostat
- peginterferon alfa 2a
- pembrolizumab
- pentostatin
- pertuzumab
- pirtobrutinib
- polatuzumab vedotin
- pomalidomide
- ponatinib
- ponesimod
- prednisolone
- prednisone
- procarbazine
- regorafenib
- retifanlimab
- rilonacept
- ripretinib
- risankizumab
- ritlecitinib
- rituximab
- romidepsin
- ropeginterferon alfa-2b
- rozanolixizumab
- ruxolitinib
- sarilumab
- satralizumab
- secukinumab
- selinexor
- siltuximab
- siponimod
- sirolimus
- sirolimus albumin-bound
- sirolimus topical
- spesolimab
- sunitinib
- sunvozertinib
- tacrolimus
- tafasitamab
- talquetamab
- tarlatamab
- teclistamab
- temozolomide
- temsirolimus
- teplizumab
- teriflunomide
- thioguanine
- thiotepa
- tildrakizumab
- tisagenlecleucel
- tislelizumab
- tocilizumab
- tofacitinib
- topotecan
- toripalimab
- tralokinumab
- tremelimumab
- triamcinolone
- ublituximab
- upadacitinib
- ustekinumab
- vamorolone
- vandetanib
- vedolizumab
- venetoclax
- vinblastine
- vincristine
- vinorelbine
- voclosporin
- zanidatamab
- zanubrutinib
- zenocutuzumab
- zongertinib
Adverse Reactions .
Serious Reactions
- hypersensitivity rxn
- anaphylactoid rxn
- anaphylaxis
- erythema multiforme
- erythema nodosum
- Stevens-Johnson syndrome
- neurotoxicity
- Guillain-Barre syndrome
- seizures
- herpes zoster (shingles)
- autoimmune disorder
- lymphadenopathy
- hypotension
- alopecia
- thrombocytopenia
Common Reactions
- injection site rxn
- irritability
- fever
- diarrhea
- fatigue
- weakness
- appetite decr. (peds patients)
- headache
- malaise
- rhinitis
- nausea
Safety/Monitoring .
Monitoring Parameters
no routine tests recommended
Look/Sound-Alike Drug Names
Recombivax HB confused with: ComVax
hepatitis B vaccine, recombinant confused with: hepatitis A vaccine, inactivated; hepatitis B immune globulin; hepatitis B vaccine recombinant, adjuvanted
Pregnancy/Lactation .
Pregnancy
Clinical Summary
may use during pregnancy; risk of fetal harm not expected based on limited human data
Lactation
Clinical Summary
may use while breastfeeding; no human data available, though risk of infant harm not expected based on vaccine properties; no human data available to assess effects on milk production
Pharmacology .
Metabolism: other; CYP450: unknown
Excretion: unknown; Half-life: unknown
Subclass: Hepatitis B (HBV) Vaccines ; Routine Adult Vaccines ; Routine Pediatric Vaccines ; Travel Vaccines
Mechanism of Action
exact mechanism of action unknown; induces antibody formation
Formulary .
No Formulary Selected
Manufacturer/Pricing .
Manufacturer: Merck & Co., Inc.
DEA/FDA: Rx
Retail Price
Estimated prices only. For current pricing, visit GoodRx.
intramuscular suspension:
- 10 mcg/mL (1 vial, 1 mL): $71.00
- 40 mcg/mL (1 vial, 1 mL): $183.00
intramuscular suspension:
- 5 mcg/0.5 mL (1 syringe, 0.5 mL): $30.00
intramuscular suspension:
- 5 mcg/0.5 mL (1 vial, 0.5 mL): $30.00
intramuscular suspension:
- 10 mcg/mL (1 syringe, 1 mL): $70.00
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.